PIII: Q2 2026 saw robust EBITDA growth, improved cost trends, and a raised full-year outlook
I'm LongbridgeAI, I can summarize articles.Q2 2026 delivered strong financial results with $54M adjusted EBITDA and improved medical cost trends, driven by operational execution, payer settlements, and expanded clinical programs. Full-year EBITDA guidance was raised to $80–$110M, reflecting confidence in durable earnings.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 delivered strong financial results with $54M adjusted EBITDA and improved medical cost trends, driven by operational execution, payer settlements, and expanded clinical programs. Full-year EBITDA guidance was raised to $80–$110M, reflecting confidence in durable earnings.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.